What is Citanest used for?

Citanest is indicated for Local anesthesia, Premature ejaculation.

What development phase is Citanest in?

Citanest is FDA-approved (marketed).

What are the side effects of Citanest?

Common side effects include Respiratory depression, Cardiovascular collapse, Cardiac arrest, Convulsions, Unconsciousness, Tremors.

What is the generic name of Citanest?

PRILOCAINE is the generic (nonproprietary) name of Citanest.

Last reviewed 2026-04-20 · How we verify

Citanest (PRILOCAINE)

FDA-approved approved Small molecule Quality 35/100

At a glance

Generic name	PRILOCAINE
Drug class	Amide Local Anesthetic [EPC]
Target	Sodium channel alpha subunits; brain (Types I, II, III)
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved
First approval	1965

Approved indications

Local anesthesia
Premature ejaculation

Common side effects

Respiratory depression
Cardiovascular collapse
Cardiac arrest
Convulsions
Unconsciousness
Tremors
Twitching
Sensations of heat
Sensations of cold
Sensations of numbness
Respiratory arrest
Nervousness

Key clinical trials

Efficacy and Safety of Combined Nanofat Injection With Either Platelet Rich Fibrin or Microneedling Versus Nanofat Injection Alone in the Treatment of Facial Atrophic Post Acne Scars (NA)
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers (PHASE2)
The Additive Effect of Exercise in Addition to Corticosteroid Injection in Plantar Fasciitis (NA)
Evaluation of Supraclavicular Brachial Plexus Blocks at Various Volumes: Impact on Optic Nerve Sheath Diameter (NA)
Virtual Reality Goggle Utilization for Venipuncture Distraction (NA)
Effect of Erector Spinae Plane Block on Cerebral Oxygenation During One-Lung Ventilation (NA)
Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face (PHASE2, PHASE3)
Using Three Different Doses of Hyperbaric Prilocaine 2% Local Anaesthetic ( 40,50 and 60mg ),Through Spinal Anaesthesia in Knee Arthroscopy Patients to Compare Time to Void (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Citanest CI brief — competitive landscape report
Citanest updates RSS · CI watch RSS